Berezhnaya S V, Yakupov E Z
Kazan, Municipal health care 'City hospital #6'.
Kazan State Medical University.
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):48-52. doi: 10.17116/jnevro20151156148-52.
To perform a differential analysis of the efficacy of combination therapy by the drugs with different modalities (mexidol, aescusan, halidorum) in outpatients with chronic cerebral ischemia (CCI), stages I- III.
A study included 50 patients with CCI of atherosclerotic, hypertensive and mixed genesis (stage I - 20 patients, stage II - 20, stage III - 10 patients). In addition to somatic therapy, patients received three courses of mexidol, halidorum and aescusan combination therapy during 6 weeks with a 3 month interval between the courses. The changes in subjective complaints and objective clinical manifestations were evaluated after each course.
The therapeutic efficacy after durable complex therapy by repeated courses of antioxidants is supported by the results of clinical and neurological examinations. Mexidol in the combination with aescusan and halidorum contributed to the improvement of cognitive, adaptive, motor functions of the patients with CCI, stages I and II. To increase treatment efficacy in patients with CCI, stage III, we recommend to use the drugs that improve cognitive functions of the patients.
对处于Ⅰ - Ⅲ期的慢性脑缺血（CCI）门诊患者，采用不同剂型药物（美西多芬、七叶皂苷钠、卤多立姆）联合治疗的疗效进行差异分析。
该研究纳入了50例患有动脉粥样硬化性、高血压性和混合性病因慢性脑缺血的患者（Ⅰ期20例，Ⅱ期20例，Ⅲ期10例）。除了躯体治疗外，患者在6周内接受了三个疗程的美西多芬、卤多立姆和七叶皂苷钠联合治疗，疗程之间间隔3个月。每个疗程后评估主观症状和客观临床表现的变化。
临床和神经学检查结果支持了通过反复疗程的抗氧化剂进行持久综合治疗后的治疗效果。美西多芬与七叶皂苷钠和卤多立姆联合使用有助于改善Ⅰ期和Ⅱ期慢性脑缺血患者的认知、适应和运动功能。为提高Ⅲ期慢性脑缺血患者的治疗效果，我们建议使用能改善患者认知功能的药物。
